Novo Nordisk A/S
NVO
$54.30
$0.020.04%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.46B | 43.59B | 42.09B | 39.35B | 37.42B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.46B | 43.59B | 42.09B | 39.35B | 37.42B |
| Cost of Revenue | 7.16B | 6.69B | 6.32B | 5.97B | 5.73B |
| Gross Profit | 38.30B | 36.90B | 35.77B | 33.38B | 31.69B |
| SG&A Expenses | 10.48B | 9.94B | 9.76B | 9.55B | 9.16B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -89.35M | -151.29M | -66.61M | -5.46M | -34.65M |
| Total Operating Expenses | 23.83B | 22.48B | 21.82B | 21.00B | 20.12B |
| Operating Income | 21.63B | 21.11B | 20.27B | 18.36B | 17.30B |
| Income Before Tax | 20.51B | 19.03B | 18.45B | 17.36B | 16.39B |
| Income Tax Expenses | 4.33B | 3.98B | 3.80B | 3.57B | 3.34B |
| Earnings from Continuing Operations | 16.18K | 15.05K | 14.65K | 13.79K | 13.05K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.18B | 15.05B | 14.65B | 13.79B | 13.05B |
| EBIT | 21.63B | 21.11B | 20.27B | 18.36B | 17.30B |
| EBITDA | 23.37B | 22.50B | 21.44B | 19.49B | 18.49B |
| EPS Basic | 3.64 | 3.38 | 3.29 | 3.09 | 2.92 |
| Normalized Basic EPS | 3.00 | 2.91 | 2.82 | 2.59 | 2.45 |
| EPS Diluted | 3.64 | 3.38 | 3.28 | 3.09 | 2.91 |
| Normalized Diluted EPS | 3.00 | 2.90 | 2.82 | 2.58 | 2.45 |
| Average Basic Shares Outstanding | 17.78B | 17.80B | 17.82B | 17.83B | 17.86B |
| Average Diluted Shares Outstanding | 17.81B | 17.83B | 17.85B | 17.87B | 17.90B |
| Dividend Per Share | 1.70 | 1.63 | 1.63 | 1.43 | 1.43 |
| Payout Ratio | 44.93% | 48.33% | 44.06% | 46.82% | 46.91% |